Federation des caisses Desjardins du Quebec’s Janux Therapeutics JANX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.9K	Buy	+1,000	New	+$13.7K	﹤0.01%	2210

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's JANX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Janux Therapeutics (JANX) in Q1 2026: 1,000 shares worth $13.9K. The stake represents ﹤0.01% of the portfolio and ranks #2210 among its holdings.

190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Federation des caisses Desjardins du Quebec held 1,000 shares of Janux Therapeutics worth $13.9K as of Q1 2026.
Janux Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q1 2026.
Janux Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2210 holding.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.